AstraZeneca commits to supply Europe with 400 million doses of COVID-19 vaccine candidate
AstraZeneca plans to produce up to 400 million doses of the University of Oxford’s COVID-19 vaccine candidate, with deliveries to begin by the end of the year.
List view / Grid view
AstraZeneca plans to produce up to 400 million doses of the University of Oxford’s COVID-19 vaccine candidate, with deliveries to begin by the end of the year.
A new agreement between the University of Oxford and AstraZeneca will allow the former's COVID-19 vaccine candidate to be manufactured and distributed.
Following the initiation of a clinical trial, a COVID-19 vaccine candidate developed by UK researchers is being manufactured in several outsourced facilities.